Latest Insider Transactions at Aurinia Pharmaceuticals Inc. (AUPH)
This section provides a real-time view of insider transactions for Aurinia Pharmaceuticals Inc. (AUPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aurinia Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aurinia Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 11
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+21.79%
|
$120,000
$3.02 P/Share
|
|
Mar 12
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
40,000
-17.6%
|
$520,000
$13.49 P/Share
|
|
Mar 12
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+14.96%
|
$120,000
$3.02 P/Share
|
|
Mar 05
2021
|
George M Milne Jr Director |
BUY
Open market or private purchase
|
Direct |
5,000
+10.0%
|
$65,000
$13.0 P/Share
|
|
Jan 29
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+30.3%
|
$475,000
$5.97 P/Share
|
|
Jan 29
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
1,200
+50.0%
|
$19,200
$16.03 P/Share
|
|
Jan 29
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Indirect |
400
+50.0%
|
$6,400
$16.03 P/Share
|
|
Jan 28
2021
|
Stephen P. Robertson EVP, General Counsel |
BUY
Open market or private purchase
|
Direct |
900
+24.86%
|
$14,400
$16.14 P/Share
|